TechCrunch | 07.29.20

Using population health analysis to improve patient care brings Sema4 a $1.1 billion valuation

Sema4’s $121 million financing came from BlackRock, Deerfield and Moore Strategic Ventures, and follows only 12 months after another $120 million institutional financing from investors, including Blackstone, Section 32, Oak HC/FT, Decheng and the Connecticut Innovation Fund.

Sema4 Press Release | 07.29.20

Sema4 Closes $121 Million Series C Led by BlackRock

Sema4 announces that BlackRock led its oversubscribed Series C financing of $121 million at a post-money valuation of over $1 billion. Additional new investors include Deerfield and Moore Strategic Ventures.

Sema4 Press Release | 07.28.20

Sema4 Increases COVID-19 Testing Capacity

Sema4’s announces additional nationwide support for governmental organizations and other entities seeking a COVID-19 testing solution that enables rapid, informed decisions with a seamless digital experience.

Sema4 Press Release | 07.15.20

Sema4 Receives Approval from NYS DOH for Sema4 Signal™ WES/WTS and PanCancer Somatic Tests

Sema4 has become the first company with a commercial laboratory to be approved by New York State for Whole Exome/Whole Transcriptome Sequencing for solid and hematologic malignancies utilizing tumor-normal analysis.
Genome Web | 07.15.20

Sema4 Nabs New York State Approval for Cancer Somatic Sequencing Tests

GenomeWeb reported on Sema4 securing approval from the New York State Department of Health to conduct its Sema4 Signal™ Whole Exome/Transcriptome Sequencing and PanCancer somatic tests.
Clinical Lab Products | 07.08.20

Sema4 Signal™ Delivers Data-driven Precision Oncology Solutions

Clinical Lab Products published a story on Sema4’s launch of Sema4 Signal™ and how it enables a holistic approach to support oncologists delivering precision medicine throughout a patient’s journey.
Sema4 Press Release| 07.08.20

Sema4 Introduces “Sema4 Signal™” Data-driven Precision Oncology Solutions

Sema4 has announced the launch of Sema4 Signal™, a new family of products and services providing data-driven precision oncology solutions with advanced analytics, digital tools, and exome-based somatic and hereditary cancer genomic tests.
Senator Chris Murphy | 06.30.20

Murphy Highlights Stamford Innovator Sema4 as “Murphy’s Innovator of the Month”

U.S. Senator Chris Murphy (Conn.) named Sema4 as his “Innovator of the Month” for June 2020.  Senator Murphy recognized Sema4 for its innovative, patient-centered approach to healthcare and for joining the fight against COVID-19.
CBS Connecticut | 06.16.20

CBS Connecticut Interviews Sema4 Founder and CEO Eric Schadt

WFSB, the CBS Connecticut affiliate, conducted a live interview with Dr. Schadt on Sema4’s work to combat COVID-19. Dr. Schadt covered Sema4’s full array of back-to-work solutions including its digital tools, the company’s partnership with the State of CT to be a testing provider, and more.

The Role of COVID-19 Testing in Getting Back to Work

Bloomberg Radio conducted a live interview with Dr. Eric Schadt, Sema4 Founder and CEO, on companies reopening their workplaces during COVID-19. Dr. Schadt discussed key considerations for businesses as they bring their employees back to the workplace, as well as Sema4’s holistic, digital end-to-end solution and partnership with the State of Connecticut.